What does Center for Beta Cell Therapy in Diabetes do?

Center for Beta Cell Therapy in Diabetes is a research organisation in Jette. Non-profit, started on 17 March 2005, 1 establishment.

What is the address of Center for Beta Cell Therapy in Diabetes?

The registered office of Center for Beta Cell Therapy in Diabetes is located at Laarbeeklaan 103, 1090 Jette.

Is Center for Beta Cell Therapy in Diabetes still active?

Yes. According to the CBE (29 October 2026) Center for Beta Cell Therapy in Diabetes is active, legal situation “Normale toestand”, started on 17 March 2005.

Is Center for Beta Cell Therapy in Diabetes registered on Peppol?

Yes, Center for Beta Cell Therapy in Diabetes is registered on the Peppol network with ID 0208:0872566468.

What is the enterprise number of Center for Beta Cell Therapy in Diabetes?

The enterprise number of Center for Beta Cell Therapy in Diabetes is BE0872566468.

When was Center for Beta Cell Therapy in Diabetes founded?

Center for Beta Cell Therapy in Diabetes was founded on 17 March 2005.

Who are the directors of Center for Beta Cell Therapy in Diabetes?

According to the 2025 annual accounts, the directors of Center for Beta Cell Therapy in Diabetes are: Bart Keymeulen, Daniël Pipeleers, Sabrina Uyttenhove.

Is Center for Beta Cell Therapy in Diabetes a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 17 March 2005; 5 annual accounts filed, latest fiscal year 2025; 3 directors known from the annual account.

How much profit did Center for Beta Cell Therapy in Diabetes make in 2025?

Center for Beta Cell Therapy in Diabetes recorded a loss after taxes of € 219,285 in financial year 2025.

What is the revenue of Center for Beta Cell Therapy in Diabetes?

As a small company, Center for Beta Cell Therapy in Diabetes is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € -184,400.

How many employees does Center for Beta Cell Therapy in Diabetes have?

According to the 2025 annual accounts, Center for Beta Cell Therapy in Diabetes has 0.1 full-time equivalents (FTE).

Center for Beta Cell Therapy in Diabetes (Non-profit)

Dossier Center for Beta Cell Therapy in Diabetes, printed on 29 October 2026 from databakkes.be/en/0872566468/center-for-beta-cell-therapy-in-diabetes. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Two loss years in a row NBB

Negative result in 2024 and 2025.

Financials

Financial year 2025

Center for Beta Cell Therapy in Diabetes from Jette, company number BE0872566468, closed financial year 2025 with a result of € -219,285 after tax. For that financial year Center for Beta Cell Therapy in Diabetes recorded a gross margin of € -184,400 and equity of € 2.6 million. Compared with financial year 2024, the result moved from € -128,261 to € -219,285. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 24, 2026.

What it is worth Healthy

€ 2.6 million

▼ 8% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Loss Caution

€ -219,285

▼ 71 % more loss than in 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 141,200

▼ 67% vs 2024

Cash and bank balances on the last day of the fiscal year.

People and assets in 2025

Full-time equivalents

0.1

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 18,023

▼ 13% vs 2024

Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Debts at end 2025

Bank debt

None

No bank loans on the last day of the fiscal year.

Owed to suppliers

€ 6,517

▼ 91% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Wages and social charges

€ 2,371

▲ 2% vs 2024

Wages, holiday pay and social contributions still to pay. No outstanding taxes.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ -205,870 Gross margin 2022: € -205,870 First fiscal year in the series	€ -199,826 Gross margin 2023: € -199,826 ▲ € 6,044 vs 2022 (€ -205,870) Favourable step	€ -93,338 Gross margin 2024: € -93,338 ▲ € 106,488 vs 2023 (€ -199,826) Favourable step	€ -184,400 Gross margin 2025: € -184,400 ▼ € 91,062 vs 2024 (€ -93,338) Unfavourable step	▼ € 91,062
Profit after taxes	€ -520,242 Profit after taxes 2022: € -520,242 First fiscal year in the series	€ -17,601 Profit after taxes 2023: € -17,601 ▲ € 502,641 vs 2022 (€ -520,242) Favourable step	€ -128,261 Profit after taxes 2024: € -128,261 ▼ € 110,660 vs 2023 (€ -17,601) Unfavourable step	€ -219,285 Profit after taxes 2025: € -219,285 ▼ € 91,024 vs 2024 (€ -128,261) Unfavourable step	▼ € 91,024
Equity	€ 2,989,677 Equity 2022: € 2,989,677 First fiscal year in the series	€ 2,972,076 Equity 2023: € 2,972,076 ▼ 1% vs 2022 (€ 2,989,677) Unfavourable step	€ 2,843,815 Equity 2024: € 2,843,815 ▼ 4% vs 2023 (€ 2,972,076) Unfavourable step	€ 2,624,530 Equity 2025: € 2,624,530 ▼ 8% vs 2024 (€ 2,843,815) Unfavourable step	▼ 8%
Total debts	€ 269,285 Total debts 2022: € 269,285 First fiscal year in the series	€ 277,719 Total debts 2023: € 277,719 ▲ 3% vs 2022 (€ 269,285) Unfavourable step	€ 474,193 Total debts 2024: € 474,193 ▲ 71% vs 2023 (€ 277,719) Unfavourable step	€ 536,297 Total debts 2025: € 536,297 ▲ 13% vs 2024 (€ 474,193) Unfavourable step	▲ 13%
Cash	€ 745,488 Cash 2022: € 745,488 First fiscal year in the series	€ 679,793 Cash 2023: € 679,793 ▼ 9% vs 2022 (€ 745,488) Unfavourable step	€ 425,699 Cash 2024: € 425,699 ▼ 37% vs 2023 (€ 679,793) Unfavourable step	€ 141,200 Cash 2025: € 141,200 ▼ 67% vs 2024 (€ 425,699) Unfavourable step	▼ 67%
Retained profit	€ 933,783 Retained profit 2022: € 933,783 First fiscal year in the series	€ 916,182 Retained profit 2023: € 916,182 ▼ 2% vs 2022 (€ 933,783) Unfavourable step	€ 787,921 Retained profit 2024: € 787,921 ▼ 14% vs 2023 (€ 916,182) Unfavourable step	€ 568,637 Retained profit 2025: € 568,637 ▼ 28% vs 2024 (€ 787,921) Unfavourable step	▼ 28%
Balance sheet total	€ 3,258,961 Balance sheet total 2022: € 3,258,961 First fiscal year in the series	€ 3,249,794 Balance sheet total 2023: € 3,249,794 Unchanged (€ 3,258,961) Unchanged	€ 3,318,008 Balance sheet total 2024: € 3,318,008 ▲ 2% vs 2023 (€ 3,249,794) Unchanged	€ 3,160,827 Balance sheet total 2025: € 3,160,827 ▼ 5% vs 2024 (€ 3,318,008) Unchanged	▼ 5%
Employees (FTE)	0.2 Employees (FTE) 2022: 0.2 First fiscal year in the series	0.2 Employees (FTE) 2023: 0.2 Unchanged (0.2) Unchanged	0.1 Employees (FTE) 2024: 0.1 ▼ 0.1 vs 2023 (0.2) Unchanged	0.1 Employees (FTE) 2025: 0.1 Unchanged (0.1) Unchanged

Key figures of Center for Beta Cell Therapy in Diabetes, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to Center for Beta Cell Therapy in Diabetes?

What happened at Center for Beta Cell Therapy in Diabetes in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jul 24, 2026 New annual accounts for financial year 2025: loss of € 219,285. Source: NBB ↗
Apr 1, 2005 New establishment in Jette. KBO
Mar 17, 2005 Start of the company according to the CBE. KBO

In short

From € 520,242 loss in 2022 to € 219,285 loss in 2025.

Original PDFs at the National Bank ↗

Management

Bart Keymeulen Daniël Pipeleers Sabrina Uyttenhove

Center for Beta Cell Therapy in Diabetes

OPUS

BETA - CELL

Drs Pipeleers & Marichal

Behind Center for Beta Cell Therapy in Diabetes are Bart Keymeulen, Daniël Pipeleers and Sabrina Uyttenhove. Daniël Pipeleers is also behind OPUS, BETA - CELL and Drs Pipeleers & Marichal. Sabrina Uyttenhove is also behind OPUS.

Directors

According to the 2025 annual accounts

Bart Keymeulen

Director

Daniël Pipeleers

Chairman of the board

Also active at: OPUS, BETA - CELL, Drs Pipeleers & Marichal

Sabrina Uyttenhove

Director

Also active at: OPUS

Establishments

Establishment units

Physical locations of this company

Registered office

Laarbeeklaan 103

1090 Jette

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 5 companies are registered at this address.

All companies at this address →

Société belge des Physiciens des Hôpitaux - Belgische Vereniging van Ziekenhuisfysici

Huis van de Geneeskundige Kring V.U.B.

Palliatief Netwerk Omega

€ 1.8 million gross margin · 2025

Diabetes Research Fonds

vzw Vlaams Farmaceutisch Studenten Overleg

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0872.566.468

VAT number

BE 0872.566.468

Registered office

Laarbeeklaan 103, 1090 Jette

Names & denominations

Center for Beta Cell Therapy in Diabetes

Enterprise type

Rechtspersoon

Legal form

Non-profit association

Legal situation

Normale toestand

Start date

17 March 2005

Peppol

Active · Active since 17 Dec 2025

Activities · NACE

Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied

Speur- en ontwikkelingswerk op natuurwetenschappelijk gebied

Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied

View on CBE Public ↗ Annual accounts (NBB) ↗

Center for Beta Cell Therapy in Diabetes

Warning lights

Financials

What happened to Center for Beta Cell Therapy in Diabetes?

Management

Directors

Establishments

Establishment units

Who else lives here?

Details

Frequently asked questions